Stanford SPARK
Stanford SPARK is an academic translational research program founded in 2006 within Stanford's School of Medicine that provides milestone-based seed funding, industry-expert mentorship, and education to Stanford researchers to advance biomedical discoveries toward clinical and commercial development.
- Company typePrivate
- Founded2006
- HeadquartersStanford, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Stanford SPARK does
Stanford SPARK is an academic translational research program housed within Stanford University School of Medicine, founded in 2006 by Daria Mochly-Rosen and Kevin Grimes. Its stated function is to bridge the gap between academic biomedical discovery and clinical or commercial application by providing milestone-based seed funding (approximately $25,000-$75,000 per project per year), weekly mentoring from a pool of 100-200+ volunteer industry experts drawn from biotech and pharma, and structured educational programming to Stanford-affiliated faculty, clinicians, postdoctoral scholars, and graduate students. Outputs flow through Stanford's Office of Technology Licensing rather than through SPARK directly; since 2006, 48 SPARK projects have been licensed to outside companies and 32 startups have been formed, with the first FDA-approved drug (Attruby/acoramidis, approved November 2024) emerging from the portfolio.
The program's business model is non-commercial: SPARK does not sell products or services and does not generate revenue in the conventional sense. It is funded by a small set of internal Stanford sources — the Maternal and Child Health Research Institute (MCHRI), Bio-X, Spectrum/NIH CTSA, the Stanford Cancer Institute, and the Dean's Office — together with in-kind support from CDD Vault for drug-discovery informatics infrastructure. Strategic value accrues upstream to Stanford via licensing royalties, equity in startups, and reputational returns, while the program's methodology has been exported through the SPARK Global Network, which by 2026 spans more than 60 academic institutions across 20+ countries on six continents. Recent downstream milestones include Bayer's acquisition of European marketing rights for Attruby (March 2025), Novartis's agreement to acquire Excellergy for up to $2 billion (April 2026), and the $85 million Series A emergence of Stylus Medicine (May 2025).
For a PE/VC/M&A audience, SPARK is best understood as an academic translational platform rather than an investable operating company. Its significance lies in (i) the validated methodology and mentor network that have produced the program's first FDA approval and large strategic-buyer transactions, (ii) the global franchise value of the SPARK brand and training infrastructure, and (iii) the optionality embedded in its pipeline of 32+ startups. The principal limitations are the absence of direct commercial revenue, dependence on a narrow set of internal Stanford funding sources, and the structural separation between SPARK's program activities and the licensing economics that flow through Stanford OTL.
Stanford SPARK firmographics
Firmographics- Name
- Stanford SPARK
- Legal name
- SPARK Stanford
- Website
- https://sparkmed.stanford.edu
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Stanford SPARK is an academic translational research program founded in 2006 within Stanford's School of Medicine that provides milestone-based seed funding, industry-expert mentorship, and education to Stanford researchers to advance biomedical discoveries toward clinical and commercial development.
- Ownership category
- akta.pro rank
Stanford SPARK industry classification
Industry- Product category
- Academic Translational Research Services
- NAICS
- Grantmaking and Giving Services (81321), Educational Support Services (611710), Voluntary Health Organizations (813212)
- akta.pro primary industry
- Health & Medical Research Grantmaking Foundations (BPAGAKAL)
- akta.pro secondary industries
- Research & Science Grantmaking Foundations (BPAGAKAI), Education Grantmaking Foundations (BPAGAKAK)
Keywords
Where Stanford SPARK is headquartered
LocationHeadquarters
- HQ city
- Stanford
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Stanford SPARK business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- Institutional Funding and Grants: SPARK operates primarily through institutional funding from Stanford University, Stanford Maternal and Child Health Research Institute (MCHRI), Stanford Bio-X, Stanford Spectrum (NIH CTSA), Stanford Cancer Institute, and departmental support. Additional in-kind support is provided by CDD Vault for drug discovery informatics.
- Technology Licensing Revenue: As projects succeed and get licensed to pharmaceutical companies or startups, Stanford receives licensing revenue. SPARK facilitates these technology transfer arrangements but does not directly generate revenue from product sales.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Stanford SPARK product offering
Product offeringCore offering
Stanford SPARK is an academic translational research program that provides Stanford researchers with milestone-based seed funding ($25K-$75K per year for two years), structured mentorship from 200+ volunteer industry experts, and education in drug discovery and development. The program moves early-stage biomedical discoveries from academic laboratories toward clinical application and commercialization through licensing, startup formation, or partnerships with pharmaceutical companies.
Product overview
Stanford SPARK is an academic translational research program—not a conventional product company—comprising multiple interconnected offerings: the core SPARK Program in Translational Research (established 2006) provides mentorship, funding, and education to Stanford researchers; the SPARK Scholars Program offers milestone-based funding ($25K-$75K/year) and hands-on advising for two years; the SPARK Course (CSB 240 A/B) teaches drug discovery and development to graduate students; and the SPARK Manual ('A Practical Guide to Drug Development in Academia') is an educational publication available in multiple languages. Weekly seminars, quarterly advisory reviews, and connections to over 100 industry advisors support the ecosystem.
Differentiator
Problem solved
Functional benefit
Brands
- SPARK GLOBAL: A network supporting the adoption of the SPARK translational research model at academic institutions worldwide, with programs in over 60 institutions across 20+ countries.
Products and services
- SPARK Program in Translational Research An academic translational research program that provides mentorship, milestone-based funding, and education to Stanford affiliates (professors, clinicians, postdoctoral scholars, and graduate students) to advance biomedical discoveries into treatments for patients. The program includes weekly coaching by volunteer industry experts and connections to commercial partners.
- SPARK Scholars (SPARKees) Program A mentorship and funding program for Stanford affiliates whose product proposals have been accepted for development, providing hands-on advising, milestone-based funding for two years, and weekly seminars with industry and academic experts.
- SPARK Course (CSB 240 A/B: A Practical Approach to Drug Discovery and Development) A graduate-level project-based course where teams of students develop their own drug discovery proposals over a quarter, covering topics including assay development, compound screening, lead optimization, toxicology testing, regulatory issues, clinical trials, and commercialization.
- SPARK: A Practical Guide to Drug Development in Academia A book published by SPARK co-founders Daria Mochly-Rosen and Kevin Grimes to help academic institutions develop their own SPARK Programs. Available in English, Chinese, Japanese, and Korean.
- SPARK Pilot Grants Milestone-based funding ranging between $25,000 and $75,000 per year for SPARK projects, contingent upon completion of prior term goals, with mandatory participation in weekly seminars and quarterly project updates.
- Industry Advisor Mentoring Over 100 volunteer industry executives and advisors provide project feedback, aid in project selection, mentor specific projects one-on-one, and facilitate introductions to potential partners or company formation.
Quantifiable outcome
- 50% of SPARK projects successfully advanced to clinical and commercial sectors
- +5 more outcomes
Companies that use Stanford SPARK
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
Stanford SPARK technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Stanford SPARK partnerships and signals
Strategic signalPartnerships
19 partnerships are on record, tiered core.
- Stanford Maternal and Child Health Research Institute (MCHRI)coreMCHRI has been supporting SPARK projects for over 7 years. Its mission to accelerate Stanford discoveries to improve the health of pregnant women and children complements SPARK's own mission. MCHRI has provided funding for numerous projects in child and maternal health, with 11 projects reaching clinic or commercial sectors.
- Stanford Medicine Dean's OfficecoreFrom its beginning in 2006, SPARK has been supported by the generosity of the Dean of the Stanford School of Medicine. Dean Lloyd Minor's ongoing financial and institutional support has been vital to the growth and expansion of SPARK.
- Stanford Bio-XcoreSPARK is grateful for the support of Bio-X, Stanford's interdisciplinary biosciences institute, bringing together biomedical and life science researchers, clinicians, engineers, physicists, and computational scientists.
- Stanford Spectrum (NIH CTSA)coreSPARK is supported by the NIH Clinical & Translational Science Award (CTSA) through the Stanford Center for Clinical and Translational Research and Education (Spectrum).
- Stanford Cancer InstitutecoreSPARK thanks the Stanford Cancer Institute for its generous support of SPARK projects advancing cancer research and treatment development.
- NovartiscoreSPARK startup Excellergy, developing a new class of allergy therapeutics called Effector Cell Response Inhibitors (ECRIs), will be acquired by Novartis in a deal worth up to $2 billion in upfront and milestone payments. Excellergy's lead molecule Exl-111 is in Phase I clinical trials.
- BridgeBio Pharma/Eidos TherapeuticscoreEidos Therapeutics, founded by SPARK scholar Isabella Graef, merged with BridgeBio to develop Attruby (acoramidis) which received FDA approval in November 2024 for ATTR-CM. Bayer acquired European marketing rights in March 2025.
- ALX OncologycoreALX Oncology, founded based on technology from SPARK advisor Chris Garcia's research, is a public company (NASDAQ: ALXO) developing Evorpacept for cancer treatment. Received FDA Orphan Drug Designation for gastric cancer.
- Astellas PharmacoreAstellas acquired rights from Auration Biotech (SPARK startup led by Peter Santa Maria) to develop a therapeutic gel for chronic tympanic membrane perforation.
- CuraSen TherapeuticscoreCuraSen, founded by SPARK scholar Mehrdad Shamloo, closed a $54.5M Series A financing and presented Phase 1b clinical data demonstrating significant increases in cerebral blood flow in patients with mild cognitive impairment or Parkinson's Disease.
- Balance TherapeuticscoreBalance Therapeutics, founded based on SPARK research by Craig Garner, raised $21M in Series A and B funding for development of treatments for cognitive function in Down syndrome. Phase 2 clinical trials ongoing in Australia.
- Globavir BiosciencescoreGlobavir Biosciences licensed a two-drug combination therapy from SPARK (Shirit Einav's research) for treatment of dengue and other viral infections. Company is committed to delivering antiviral therapies to the developing world.
- Eiger BioPharmaceuticals (NASDAQ: EIGR)coreEiger BioPharmaceuticals, founded by Jeffrey Glenn, licensed SPARK technology and ran Phase IB clinical trials. Company is public (NASDAQ: EIGR) and performing multiple phase II studies worldwide.
- SPARK Global NetworkcoreA number of academic institutions have successfully developed their own SPARK programs, resulting in a global community of translational scientists. SPARK at Stanford actively supports US and international partners with visits, guest lectures, and more. Over 60 institutions in 20+ countries participate.
- SPARK-BIHcoreSPARK-BIH in Berlin celebrated its 10th anniversary. It has grown into a key player of the translational ecosystem, providing milestone-based funding, mentorship, education, and a global network. Over 220 participants attended the anniversary celebration.
- UniQuest/University of QueenslandcoreUniQuest, the commercialization arm of University of Queensland in Australia, joined SPARK GLOBAL Network. Will launch SPARK UniQuest in early 2026 under leadership of Dr. Idalia Ridley.
- SPARK The MidlandscoreSPARK The Midlands, based at Aston University in England, hosted the SPARK Europe Showcase where 77 projects pitched to investors. First UK branch of SPARK GLOBAL.
- Stylus MedicinecoreStylus Medicine emerged from stealth in May 2025 with $85M Series A financing to develop in vivo genetic medicines platform. Founded by Stanford professors who received SPARK funding and support. Developing novel therapeutic-grade recombinases with lipid nanoparticle delivery.
- National Institute for Pharmaceutical Research and Development (NIPRD)coreNIPRD in Nigeria will collaborate with SPARK GLOBAL to host SPARK Translational Research Bootcamp and Conference in Abuja, Nigeria in February 2026, including the launch of SPARK Nigeria program.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
Stanford SPARK competitors and assessment
Company assessmentRegional players
- BioGenerator (St. Louis): BioGenerator creates and funds bio startups from academic research in the St. Louis region, combining lab space, seed funding, and venture creation services. Comparable academic-to-startup pipeline model but operating in a different geographic ecosystem than SPARK.
Direct peers
- Harvard Blavatnik Biomedical Accelerator: Harvard's Blavatnik Biomedical Accelerator provides funding, industry mentorship, and translational support to Harvard faculty for moving discoveries toward commercialization. Closest direct competitor in mission and structure among top US academic accelerators.
- Vanderbilt Center for Neuroscience Drug Discovery (VCNDD): VCNDD translates academic neuroscience discoveries into clinical drug candidates, combining medicinal chemistry, pharmacology, and industry-style project management. Comparable academic drug discovery translation model with industry advisor involvement.
- UCSF Catalyst Program: UCSF Catalyst provides translational awards and industry mentoring to advance UCSF research toward clinical and commercial applications. Comparable academic-to-commercial bridge program at a peer biomedical research institution.
- Penn Medicine Center for Innovation (PCI): Penn's translational research and commercialization arm provides pilot funding, mentorship, and industry access to Penn faculty. Operates a similar milestone-based funding model with industry advisors to advance discoveries to clinic and market.
- SPARK Berlin / SPARK-BIH: SPARK-BIH at the Berlin Institute of Health is the most established international replica of the Stanford SPARK model, providing milestone-based funding, mentorship, and education to academic researchers. Direct sibling program under SPARK GLOBAL, comparable mission and methodology.
Broad incumbents
- NCATS / NIH Cures Acceleration Network: NIH National Center for Advancing Translational Sciences operates the broader federal translational research mission, funding academic-to-clinical translation across the US. Stanford Spectrum (NIH CTSA) already partners with SPARK, and NCATS represents the macro-scale public-sector version of SPARK's mission.
- Cures Within Reach: Non-profit that funds repurposing of existing drugs for new indications, providing grant funding and partnerships to academic researchers. Comparable grantmaking-and-mentorship model focused on translational outcomes, though not tied to a single university.
Others
- Wellcome Leap: Wellcome Leap funds bold translational research programs with milestone-based structures to accelerate health breakthroughs. Operates at much larger scale and on a foundation model, but shares SPARK's emphasis on milestone-driven translation of academic discoveries.
- Milken Institute FasterCures: Non-profit think tank and convener focused on accelerating medical research translation. Thematically aligned with SPARK's mission but operates through policy, convening, and capital-formation initiatives rather than direct project funding.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Stanford SPARK social profiles
Digital presenceStanford SPARK financial estimates
Financial estimateRevenue estimate
Valuation estimate
Stanford SPARK leadership team
Management profileNumber of profiles
Profiles9 records
Stanford SPARK subsidiaries and ownership
Company hierarchySubsidiaries1 record
Stanford SPARK funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Stanford SPARK M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Stanford SPARK
What does Stanford SPARK do?
Stanford SPARK is an academic translational research program that provides Stanford researchers with milestone-based seed funding ($25K-$75K per year for two years), structured mentorship from 200+ volunteer industry experts, and education in drug discovery and development. The program moves early-stage biomedical discoveries from academic laboratories toward clinical application and commercialization through licensing, startup formation, or partnerships with pharmaceutical companies.
Is Stanford SPARK a public or private company?
Stanford SPARK is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Stanford SPARK founded?
Stanford SPARK was founded in 2006. It employs 11 to 50 people.
Where is Stanford SPARK based?
Stanford SPARK is headquartered in Stanford, United States, in the North America region.
How does Stanford SPARK make money?
Two revenue lines are on record. Institutional Funding and Grants are the primary driver. The others are technology Licensing Revenue.
Who are Stanford SPARK's main competitors?
BioGenerator (St. Louis) is listed as a regional player. Direct peers are Harvard Blavatnik Biomedical Accelerator, Vanderbilt Center for Neuroscience Drug Discovery (VCNDD), UCSF Catalyst Program, Penn Medicine Center for Innovation (PCI) and SPARK Berlin / SPARK-BIH. Broad incumbents are NCATS / NIH Cures Acceleration Network and Cures Within Reach. Others are Wellcome Leap and Milken Institute FasterCures.
Does Stanford SPARK have an API?
No public API is recorded for Stanford SPARK.
What industry is Stanford SPARK in?
Stanford SPARK's product category is Academic Translational Research Services. Its primary akta.pro industry code is BPAGAKAL, Health & Medical Research Grantmaking Foundations, with a secondary code of BPAGAKAI, Research & Science Grantmaking Foundations. Its NAICS code is 81321.